Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 313-320

  Jung, Suk Hyun ^a,b   Lim, Deok Hwi ^a   Jung, Soon Hwa ^a   Lee, Jung Eun ^a,b   Jeong, Kyu Sung ^b   Seong, Hasoo ^a   Shin, Byung Cheol ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Amphotericin B; Antifungal activity; Cytotoxicity; Hematotoxicity; Lipid nanoparticle

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; LIPID; MACROGOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD TOXICITY; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG UPTAKE; EMULSION; ERYTHROCYTE; EVAPORATION; FUNGUS GROWTH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; LIPID COMPOSITION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ZETA POTENTIAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; FUNGI; HEMOLYSIS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 67349131909     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.02.021     Document Type: Article

References (40)

1. Adams M., and Kwon G.S. Spectroscopic investigation of aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles. J. Pharm. Pharm. Sci. 7 S1 (2004) 1-6
2. Adler-Moore J.P., and Proffitt R.T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3 (1993) 429-450
3. Antoniadou A., and Dupont B. Lipid formulations of amphotericin B: where are we today?. J. Med. Mycol. 15 (2005) 230-238
4. Bhamra R., Sa'Ad A., Bolcsak L.E., Janoff A.S., and Swenson C.E. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41 (1997) 886-892
5. Espada R., Valdespina S., Alfonso C., Rivas G., and Ballesteros M.P. Effect of aggregation state on the toxicity of defferent amphotericin B preparations. Int. J. Pharm. 361 (2008) 64-69
6. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J.P., and Ygartua P. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158 (1997) 19-27
7. Fatouros D.G., Bergenstahl B., and Mullertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur. J. Pharm. Sci. 31 (2007) 85-94
8. Fielding R.M., Smith P.C., Wang L.H., Porter J., and Guo L.S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35 (1991) 1208-1213
9. ®). Int. J. Pharm. 263 (2003) 51-60
10. ®). Int. J. Pharm. 265 (2003) 37-45
11. ®), with commercial lipid-based formulations. Int. J. Pharm. 267 (2003) 101-112
12. Hac-wydro K., and Dynarowicz-Latka P. Interaction between nystatin and natural membrane lipids in Langmuir monolayers-the role of a phospholipid in the mechanism of polyenes mode of action. Biophys. Chem. 123 (2006) 155-162
13. Johnson E.M., Ojwang J.O., Szekely A., Wallace T.L., and Warnock D.W. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulaltion. Antimicrob. Agents Chemother. 42 (1998) 1412-1416
14. Kleinberg M. What is the current and future status of conventional amphotericin B?. Int. J. Antimicrob. Agents 27S (2006) S12-S16
15. Larabi M., Gulik A., Dedjeu J.P., Legrand P., Barratt G., and Cheron M. New lipid formulation of amphotericin B: spectral and microscopic analysis. Biochim. Biophys. Acta 1664 (2004) 172-181
16. Lian T., and Ho R.Y. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 90 (2001) 667-680
17. Mazerski J., and Borowski E. Molecular dynamics of amphotericin B. II. Dimer in water. Biophys. Chem. 57 (1996) 205-217
18. Minones Jr. J., Conde O., Minones J., Patino J.M.R., and Seoane R. Amphotericin B-Dipalmitoyl phosphatidyl glycerol interations responsible for the reduced toxicity of liposomal formulations: a monolayer study. Langmuir 18 (2002) 8601-8608
19. Moghimi S.M., and Patel H.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv. Drug Deliv. Rev. 32 (1998) 45-60
20. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
21. Moribe K., Maruyama K., and Iwatsuru M. Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives. Int. J. Pharm. 188 (1999) 193-202
22. Moribe K., Maruyama K., and Iwatsuru M. Molecular localization and state of amphotericin B in PEG liposomes. Int. J. Pharm. 193 (1999) 97-106
23. Müller R.H., Radtke M., and Wissing S.A. Solid lipid nanoparticle (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 1 (2002) S131-S155
24. Müller R.H. Lipid nanoparticles: recent advances. Adv. Drug Deliv. Rev. 59 (2007) 375-376
25. Nahar M., Mishra D., Dubey V., and Jain N.K. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine: NBM 4 (2008) 252-261
26. Oliveira M.C.D., Boutet V., Fattal E., Boquet D., Grognet J.M., Couvreur P., and Deverre J.R. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sci. 67 (2000) 1625-1637
27. Olsen S.J., Swerdel M.R., Blue B., Clark J.M., and Bonner D.P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43 (1991) 831-835
28. Owens III D.E., and Peppas N.A. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
29. Perkins W.R., Ahmad I., Li X., Hirsh D.J., Masters G.R., Fecko C.J., Lee J.K., Ali S., Nguyen J., Schupsky J., Herbert C., Janoff A.S., and Mayhew E. Novel therapeutic nano-particle (lipocores): trapping poorly water soluble sompounds. Int. J. Pharm. 200 (2000) 27-39
30. Pestana K.C., Formariz T.P., Franzini C.M., Sarmento V.H.V., Chiavacci L.A., Scarpa M.V., Egito E.S.T., and Oliveira A.G. Oil-in-water lecithin-based microemulsions as a potential delivery system for amphotericin B. Colloids Surf. B: Biointerfaces 66 (2008) 253-259
31. Shimada K., Matsuo S., Sadzuka Y., Miyagishima A., Nozawa Y., Hirota S., and Sonobe T. Deternination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int. J. Pharm. 203 (2000) 255-263
32. Sionov E., Mendlovic S., and Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53 (2006) 131-139
33. Song C.X., Labhasetwar V., Murphy H., Qu X., Humphrey W.R., Shebuski R.J., and Levy R.J. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivey. J. Control. Rel. 43 (1997) 197-212
34. Tadros T., Izquierdo P., Esquena J., and Solans C. Formation and stability of nano-emulsions. Adv. Colloid Interface Sci. 108-109 (2004) 303-318
35. Tamilvanan S. Oil-in-water lipid emulsions; implications for parenteral and ocular delivering systems. Prog. Lipid Res. 43 (2004) 489-533
36. Turgut M., Özsunar Y., Öncü S., Akyüz O., Ertugrul M.B., Tekin C., Gültekin B., and Sakarya S. Invasive fungal granuloma of the brain caused by Aspergillus fumigatus: a case report and review of the literature 69 (2008) 169-174
37. Wasan K.W., Rosenblum M.G., Cheung L., and Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38 (1994) 223-227
38. Wong-Beringer A., Jacobs R.A., and Guglielmo B.J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin. Infect. Dis. 27 (1998) 603-618
39. Yu B.G., Okano T., Kataoka K., Sardari S., and Kwon G.S. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(β-benzyl-L-aspartate) micelles. J. Control. Rel. 56 (1998) 285-291
40. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16 (1995) 157-182